Related Experiment Video
Updated: Jan 26, 2026
06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
10.1K
Evaluating crisaborole as a treatment option for atopic dermatitis
Vignesh Ramachandran1, Abigail Cline1, Steven R Feldman1,2,3,4
1a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
Expert Opinion on Pharmacotherapy
|April 20, 2019
Summary
Crisaborole, a new topical treatment for atopic dermatitis (AD), shows modest short-term efficacy. Further head-to-head studies are needed to determine its clinical utility against existing therapies for managing eczema.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic, pruritic skin condition impacting quality of life and healthcare costs.
- Current AD management faces challenges due to limited treatment options.
- Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, is a new therapeutic option for AD.
Purpose of the Study:
- To review crisaborole's efficacy and properties in managing atopic dermatitis.
- To discuss crisaborole's role in AD treatment based on clinical trial data.
Main Methods:
- Systematic review of Phase II, Phase III, and post-marketing studies on crisaborole.
- Literature search using PubMed, Google Scholar, keywords, MeSH, and Boolean operations.
- Discussion of crisaborole's chemistry, pharmacokinetics, pharmacodynamics, and metabolism.
Main Results:
- Crisaborole demonstrated modest efficacy in short-term clinical trials for atopic dermatitis.
- As a non-steroidal agent, crisaborole may offer an alternative to topical corticosteroids, potentially alleviating steroid phobia.
- Further head-to-head trials are required to compare crisaborole's efficacy against topical corticosteroids and tacrolimus.
Conclusions:
- Crisaborole presents a novel topical treatment option for atopic dermatitis.
- Its long-term clinical utility and adherence factors require further investigation.
- Comparative studies are essential to establish crisaborole's place in the AD treatment landscape.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
01:22Alzheimer's Disease: Treatment
850
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
850
01:27Open Angle Glaucoma: Treatment
973
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
973
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
03:00Self-Evaluation: Self-Enhancement and Self-Verification
5.8K
Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.8K
01:20Myasthenia Gravis: Overview and Treatment
2.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.9K